Xing Xiao-Yu, Zhang Wei, Liu Li-Ya, Han Li-Ping
Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China.
World J Clin Cases. 2024 Feb 26;12(6):1111-1119. doi: 10.12998/wjcc.v12.i6.1111.
Neuroendocrine neoplasms of the female genital tract are rare.
To enhance our clinical understanding of neuroendocrine carcinoma (NEC) of the ovary.
A retrospective review was conducted on 12 patients diagnosed with NEC of the ovary, analyzing clinicopathological characteristics, treatment modalities, and survival status.
The median age at diagnosis was 34.5 years (range: 20 to 62 years). Among the 12 cases, 9 were small cell carcinoma of the ovary and 3 were large cell NEC. Five cases were stage I tumors, one case was stage IV, and six cases were stage III. Eleven patients underwent surgery as part of their treatment. All patients received adjuvant chemotherapy. Among the 12 patients, one patient received radiotherapy, and one patient with a BRCA2 mutation was administered PARP inhibitor maintenance after chemotherapy. The median progression-free survival was 13 months, and the median overall survival was 19.5 months. Four cases remained disease-free, while eight cases experienced tumor recurrence, including three cases that resulted in death due to disease recurrence.
NEC of the ovary is a rare condition that is more common in women of childbearing age and is associated with aggressive behavior and poor clinical outcomes. Surgical resection remains the mainstay of treatment, with some patients benefiting from adjuvant chemoradiation therapy.
女性生殖道神经内分泌肿瘤较为罕见。
增强我们对卵巢神经内分泌癌（NEC）的临床认识。
对12例诊断为卵巢NEC的患者进行回顾性研究，分析其临床病理特征、治疗方式及生存状况。
诊断时的中位年龄为34.5岁（范围：20至62岁）。12例病例中，9例为卵巢小细胞癌，3例为大细胞NEC。5例为Ⅰ期肿瘤，1例为Ⅳ期，6例为Ⅲ期。11例患者接受了手术治疗。所有患者均接受辅助化疗。12例患者中，1例接受了放疗，1例携带BRCA2突变的患者在化疗后接受了PARP抑制剂维持治疗。中位无进展生存期为13个月，中位总生存期为19.5个月。4例患者疾病无进展，8例患者出现肿瘤复发，其中3例因疾病复发死亡。
卵巢NEC是一种罕见疾病，在育龄女性中更为常见，具有侵袭性且临床预后较差。手术切除仍是主要治疗方法，部分患者可从辅助放化疗中获益。
